<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01300572</url>
  </required_header>
  <id_info>
    <org_study_id>2468.00</org_study_id>
    <secondary_id>NCI-2011-00150</secondary_id>
    <secondary_id>2468.00A</secondary_id>
    <secondary_id>2468</secondary_id>
    <secondary_id>2468.00</secondary_id>
    <secondary_id>P01CA044991</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT01300572</nct_id>
  </id_info>
  <brief_title>Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS</brief_title>
  <official_title>A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (Anti-CD45) Antibody Followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and maximum tolerated dose of yttrium Y 90
      anti-cluster of differentiation 45 (CD45) monoclonal antibody BC8 (90Y-BC8) followed by donor
      stem cell transplant in treating patients with acute myeloid leukemia (AML), acute
      lymphoblastic leukemia (ALL), or myelodysplastic syndrome (MDS) that is likely to come back
      or spread. Giving chemotherapy drugs, such as fludarabine phosphate (FLU), and total-body
      irradiation (TBI) before a donor peripheral blood stem cell (PBSC) or bone marrow transplant
      helps stop the growth of cancer or abnormal cells and helps stop the patient's immune system
      from rejecting the donor's stem cells. Radiolabeled monoclonal antibodies, such as 90Y-BC8,
      can find cancer cells and carry cancer-killing substances to them without harming normal
      cells. When the healthy stem cells from a donor are infused into the patient they may help
      the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
      Sometimes the transplanted cells from a donor can make an immune response against the body's
      normal cells. Giving FLU, 90Y-BC8, and TBI before the transplant together with cyclosporine
      and mycophenolate mofetil after the transplant may stop this from happening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the maximum tolerated dose (MTD) of radiation delivered via 90Y-DOTA-BC8
      (90Y-BC8) when combined with FLU and 2 Gy TBI as a preparative regimen for patients aged &gt;=
      18 with advanced AML, ALL, and high-risk MDS.

      SECONDARY OBJECTIVES:

      I. To determine disease response and duration of remission.

      II. To determine the rates of engraftment and donor chimerism resulting from this combined
      preparative regimen, and to correlate level of donor chimerism with estimated radiation doses
      delivered to hematopoietic tissues via antibody.

      OUTLINE:

      PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12 and
      FLU intravenously (IV) over 30 minutes on days -4 to -2.

      TRANSPLANTATION: Patients undergo TBI followed by allogeneic PBSC or bone marrow transplant
      on day 0.

      GRAFT-VS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive mycophenolate mofetil orally (PO)
      or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days
      0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive
      cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or
      100 (for patients with unrelated donors) with taper to day 180.

      After completion of study treatment, patients are followed up at 6, 9, 12, 18, and 24 months,
      and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">November 22, 2019</completion_date>
  <primary_completion_date type="Actual">October 29, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The MTD of Radiation Delivered Via 90Y-DOTA-BC8 When Combined With FLU and 2 Gy TBI as a Preparative Regimen for Patients Aged â‰¥ 18 With Advanced AML, ALL, and High-risk MDS.</measure>
    <time_frame>Within the first 30 days following transplant</time_frame>
    <description>The MTD will be defined as the dose that is associated with a true DLT rate of 25%. The highest dose achieved was 28 Gy but none of the patients experienced a DLT. Thus, the MTD was not reached.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of Remission</measure>
    <time_frame>4 weeks after transplant</time_frame>
    <description>Number of participants who are in complete remission (CR) 4 weeks after transplant. CR is defined as complete resolution of all signs of myelodysplasia or leukemia for at least 4 weeks with all of the following:
Normal bone marrow with blasts &lt;5% with normal cellularity, normal megakaryopoiesis, &gt; 15% erythropoiesis and &gt; 25% granulocytopoiesis
Normalization of blood counts (no blasts, platelets &gt; 100000/mm3, granulocytes &gt;1500/mm3)
No extramedullary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>100 days after transplant</time_frame>
    <description>Number of study participants who are alive and remains in complete remission after transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Remission</measure>
    <time_frame>1 year</time_frame>
    <description>Median time to relapse after achieving complete remission (CR). CR is defined as complete resolution of all signs of myelodysplasia or leukemia for at least 4 weeks with all of the following:
Normal bone marrow with blasts &lt;5% with normal cellularity, normal megakaryopoiesis, &gt; 15% erythropoiesis and &gt; 25% granulocytopoiesis
Normalization of blood counts (no blasts, platelets &gt; 100000/mm3, granulocytes &gt;1500/mm3)
No extramedullary disease.
Relapse Criteria:
After CR: &gt;5% blasts in the bone marrow and/or peripheral blood
After partial remission (PR): increase of blasts cells in the marrow to &gt;50% of those during PR
Extramedullary disease confirmed cytologically or histologically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of Absorbed Radiation Doses to Normal Organs, Marrow and Tumor</measure>
    <time_frame>Approximately day -20 to day -12 prior to transplant</time_frame>
    <description>The amount of energy absorbed per unit weight of the organ or tissue is called absorbed dose and is expressed in units of gray (Gy). One gray dose is equivalent to one joule radiation energy absorbed per kilogram of organ or tissue weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Number of participants who are still alive after transplant with or without disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Acute GvHD</measure>
    <time_frame>Up to 84 days post-transplant</time_frame>
    <description>Number of participants who developed acute GVHD post-transplant, aGVHD stages:
Skin: a maculopapular eruption involving &lt; 25% BSA a maculopapular eruption involving 25 - 50% BSA generalized erythroderma generalized erythroderma with bullous formation and often with desquamation
Liver:
bilirubin 2.0 - 3.0 mg/100 mL bilirubin 3 - 5.9 mg/100 mL bilirubin 6 - 14.9 mg/100 mL bilirubin &gt; 15 mg/100 mL
Gut:
Diarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients with visible bloody diarrhea are at least stage 2 gut and grade 3 overall.
aGVHD Grades Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Donor Chimerism</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
    <description>Number of participants who has 100% donor chimerism within 100 days after transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Engraftment</measure>
    <time_frame>Up to 84 days post-transplant</time_frame>
    <description>Average number of days to ANC &gt;= 500 after transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Non-relapse Mortality</measure>
    <time_frame>Within the first 100 days following transplant</time_frame>
    <description>Transplant-related deaths within 100 days after transplant</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Previously Treated Myelodysplastic Syndrome</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Refractory Anemia With Excess Blasts</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Y-90-BC8 &amp; Allogeneic Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.
TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Undergo allogeneic bone marrow transplant</description>
    <arm_group_label>Y-90-BC8 &amp; Allogeneic Transplant</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic PBSC or bone marrow transplant</description>
    <arm_group_label>Y-90-BC8 &amp; Allogeneic Transplant</arm_group_label>
    <other_name>allogeneic stem cell transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Y-90-BC8 &amp; Allogeneic Transplant</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Y-90-BC8 &amp; Allogeneic Transplant</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Indium In 111 Anti-CD45 Monoclonal Antibody BC8</intervention_name>
    <description>Given IV (dosimetric dose)</description>
    <arm_group_label>Y-90-BC8 &amp; Allogeneic Transplant</arm_group_label>
    <other_name>In 111 MOAB BC8</other_name>
    <other_name>In 111 Monoclonal Antibody BC8</other_name>
    <other_name>Indium In 111 Monoclonal Antibody BC8</other_name>
    <other_name>monoclonal antibody BC8, indium In 111</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Y-90-BC8 &amp; Allogeneic Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Y-90-BC8 &amp; Allogeneic Transplant</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic PBSC transplant</description>
    <arm_group_label>Y-90-BC8 &amp; Allogeneic Transplant</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Y-90-BC8 &amp; Allogeneic Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Y-90-BC8 &amp; Allogeneic Transplant</arm_group_label>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8</intervention_name>
    <description>Given via central line (therapeutic dose)</description>
    <arm_group_label>Y-90-BC8 &amp; Allogeneic Transplant</arm_group_label>
    <other_name>90Y Anti-CD45 MoAb BC8</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have advanced AML, ALL or high-risk MDS meeting one of the following
             descriptions:

               -  AML or ALL beyond first remission (i.e., having relapsed at least one time after
                  achieving remission in response to a treatment regimen)

               -  AML or ALL representing primary refractory disease (i.e., having failed to
                  achieve remission at any time following one or more prior treatment regimens)

               -  AML evolved from myelodysplastic or myeloproliferative syndromes; or

               -  MDS expressed as refractory anemia with excess blasts (RAEB) or chronic
                  myelomonocytic leukemia (CMML) by French-American-British (FAB) criteria

          -  Patients not in remission must have CD45-expressing leukemic blasts; patients in
             remission do not require phenotyping and may have leukemia previously documented to be
             CD45 negative (because in remission patients, virtually all antibody binding is to
             non-malignant cells which make up &gt;= 95% of nucleated cells in the marrow)

          -  Patients should have a circulating blast count of less than 10,000/mm^3 (control with
             hydroxyurea or similar agent is allowed)

          -  Patients must have an estimated creatinine clearance greater than 50/ml per minute
             (serum creatinine value must be within 28 days prior to registration)

          -  Bilirubin &lt; 2 times the upper limit of normal

          -  Aspartate aminotransferase (AST) and alanine transaminase (ALT) &lt; 2 times the upper
             limit of normal

          -  Eastern Cooperative Oncology Group (ECOG) =&lt; 2 or Karnofsky &gt;= 70

          -  Patients must have an expected survival of &gt; 60 days and must be free of active
             infection

          -  Patients must have an human leukocyte antigen (HLA)-identical sibling donor or an
             HLA-matched unrelated donor who meets standard Seattle Cancer Care Alliance (SCCA)
             and/or National Marrow Donor Program (NMDP) or other donor center criteria for PBSC or
             bone marrow donation, as follows:

               -  Related donor: related to the patient and genotypically or phenotypically
                  identical for HLA-A, B, C, DRB1 and DQB1; phenotypic identity must be confirmed
                  by high-resolution typing

               -  Unrelated donor:

                    -  Matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing; OR
                       mismatched for a single allele without antigen mismatching at HLA-A, B or C
                       as defined by high resolution typing but otherwise matched for HLA-A, B, C,
                       DRB1 and DQB1 by high resolution typing

                    -  Doors are excluded when preexisting immunoreactivity is identified that
                       would jeopardize donor hematopoietic cell engraftment; this determination is
                       based on the standard practice of the individual institution; the
                       recommended procedure for patients with 10 of 10 HLA allele level
                       (phenotypic) match is to obtain panel reactive antibody (PRA) screens to
                       class I and class II antigens for all patients before hematopoietic cell
                       transplant (HCT); if the PRA shows &gt; 10% activity, then flow cytometric or B
                       and T cell cytotoxic cross matches should be obtained; the donor should be
                       excluded if any of the cytotoxic cross match assays are positive; for those
                       patients with and HLA class I allele mismatch, flow cytometric or B and T
                       cell cytotoxic cross matches should be obtained regardless of the PRA
                       results; a positive anti-donor cytotoxic crossmatch is an absolute donor
                       exclusion

                    -  Patient and donor pairs homozygous at a mismatched allele in the graft
                       rejection vector are considered a two-allele mismatch; i.e., the patient is
                       A*0101 and the donor is A*0102, and this type of mismatch is not allowed

          -  DONOR: Donors must meet HLA matching criteria and standard SCCA and/or National Marrow
             Donor Program (NMDP) or other donor center criteria for PBSC or bone marrow donation

        Exclusion Criteria:

          -  Circulating human anti-mouse antibody (HAMA)

          -  Prior radiation to maximally tolerated levels to any critical normal organ, or &gt; 20 Gy
             prior radiation to large areas of the bone marrow (e.g., external radiation therapy to
             whole pelvis)

          -  Patients may not have symptomatic coronary artery disease and may not be on cardiac
             medications for anti-arrhythmic or inotropic effects

          -  Left ventricular ejection fraction &lt; 35%

          -  Corrected diffusion lung capacity of carbon monoxide (DLCO) &lt; 35% or receiving
             supplemental continuous oxygen

          -  Liver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of
             portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy,
             uncorrectable hepatic synthetic dysfunction as evidenced by prolongation of the
             prothrombin time, ascites related to portal hypertension, bacterial or fungal liver
             abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease

          -  Patients who are known to be seropositive for human immunodeficiency virus (HIV)

          -  Perceived inability to tolerate diagnostic or therapeutic procedures

          -  Active central nervous system (CNS) leukemia at time of treatment

          -  Women of childbearing potential who are pregnant (beta-human chorionic gonadotropin
             positive [HCG+]) or breast feeding

          -  Fertile men and women unwilling to use contraceptives during and for 12 months
             post-transplant

          -  Inability to understand or give an informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda Sandmaier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 15, 2011</study_first_submitted>
  <study_first_submitted_qc>February 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2011</study_first_posted>
  <results_first_submitted>October 18, 2018</results_first_submitted>
  <results_first_submitted_qc>January 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2019</results_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Brenda Sandmaier</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT01300572/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This protocol is open to participants age 18 and above, of either gender and any race/ethnicity. The study is looking at the use of Y-90-DOTA-BC8 in conjunction with a standard reduced-intensity transplant regimen.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)</title>
          <description>PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.
TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant
Cyclosporine: Given PO or IV
Fludarabine Phosphate: Given IV
Indium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>HAMA + post dosimetry</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)</title>
          <description>Study participants will receive an infusion of 0.5 mg/kg of ideal body weight of DOTA-BC8 trace labeled with ~5-10 mCi of Indium-111 to evaluate biodistribution and calculate the radiation absorbed doses to major organs and the whole body. The subsequent therapy infusion of Yttrium-90-DOTA-BC8 will deliver an amount of Yttrium-90 calculated not to exceed the target dose to the critical normal organ receiving the highest radiation dose. The therapy dose will be administered on approximately day -12 of the preparative regimen, which will typically be approximately 1 to 2 weeks after the biodistribution dose.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The MTD of Radiation Delivered Via 90Y-DOTA-BC8 When Combined With FLU and 2 Gy TBI as a Preparative Regimen for Patients Aged â‰¥ 18 With Advanced AML, ALL, and High-risk MDS.</title>
        <description>The MTD will be defined as the dose that is associated with a true DLT rate of 25%. The highest dose achieved was 28 Gy but none of the patients experienced a DLT. Thus, the MTD was not reached.</description>
        <time_frame>Within the first 30 days following transplant</time_frame>
        <population>Study participants who completed the study regimen.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)</title>
            <description>Study participants will receive an infusion of 0.5 mg/kg of ideal body weight of DOTA-BC8 trace labeled with ~5-10 mCi of Indium-111 to evaluate biodistribution and calculate the radiation absorbed doses to major organs and the whole body. The subsequent therapy infusion of Yttrium-90-DOTA-BC8 will deliver an amount of Yttrium-90 calculated not to exceed the target dose to the critical normal organ receiving the highest radiation dose. The therapy dose will be administered on approximately day -12 of the preparative regimen, which will typically be approximately 1 to 2 weeks after the biodistribution dose.</description>
          </group>
        </group_list>
        <measure>
          <title>The MTD of Radiation Delivered Via 90Y-DOTA-BC8 When Combined With FLU and 2 Gy TBI as a Preparative Regimen for Patients Aged â‰¥ 18 With Advanced AML, ALL, and High-risk MDS.</title>
          <description>The MTD will be defined as the dose that is associated with a true DLT rate of 25%. The highest dose achieved was 28 Gy but none of the patients experienced a DLT. Thus, the MTD was not reached.</description>
          <population>Study participants who completed the study regimen.</population>
          <units>Gy</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achievement of Remission</title>
        <description>Number of participants who are in complete remission (CR) 4 weeks after transplant. CR is defined as complete resolution of all signs of myelodysplasia or leukemia for at least 4 weeks with all of the following:
Normal bone marrow with blasts &lt;5% with normal cellularity, normal megakaryopoiesis, &gt; 15% erythropoiesis and &gt; 25% granulocytopoiesis
Normalization of blood counts (no blasts, platelets &gt; 100000/mm3, granulocytes &gt;1500/mm3)
No extramedullary disease.</description>
        <time_frame>4 weeks after transplant</time_frame>
        <population>Study participants who completed the study regimen</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)</title>
            <description>PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.
TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant
Cyclosporine: Given PO or IV
Fludarabine Phosphate: Given IV
Indium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of Remission</title>
          <description>Number of participants who are in complete remission (CR) 4 weeks after transplant. CR is defined as complete resolution of all signs of myelodysplasia or leukemia for at least 4 weeks with all of the following:
Normal bone marrow with blasts &lt;5% with normal cellularity, normal megakaryopoiesis, &gt; 15% erythropoiesis and &gt; 25% granulocytopoiesis
Normalization of blood counts (no blasts, platelets &gt; 100000/mm3, granulocytes &gt;1500/mm3)
No extramedullary disease.</description>
          <population>Study participants who completed the study regimen</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <description>Number of study participants who are alive and remains in complete remission after transplant.</description>
        <time_frame>100 days after transplant</time_frame>
        <population>Study participants who completed study regimen and in CR after transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)</title>
            <description>PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.
TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant
Cyclosporine: Given PO or IV
Fludarabine Phosphate: Given IV
Indium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>Number of study participants who are alive and remains in complete remission after transplant.</description>
          <population>Study participants who completed study regimen and in CR after transplant.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Remission</title>
        <description>Median time to relapse after achieving complete remission (CR). CR is defined as complete resolution of all signs of myelodysplasia or leukemia for at least 4 weeks with all of the following:
Normal bone marrow with blasts &lt;5% with normal cellularity, normal megakaryopoiesis, &gt; 15% erythropoiesis and &gt; 25% granulocytopoiesis
Normalization of blood counts (no blasts, platelets &gt; 100000/mm3, granulocytes &gt;1500/mm3)
No extramedullary disease.
Relapse Criteria:
After CR: &gt;5% blasts in the bone marrow and/or peripheral blood
After partial remission (PR): increase of blasts cells in the marrow to &gt;50% of those during PR
Extramedullary disease confirmed cytologically or histologically.</description>
        <time_frame>1 year</time_frame>
        <population>Study participants who relapsed after achieving complete remission after transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)</title>
            <description>PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.
TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant
Cyclosporine: Given PO or IV
Fludarabine Phosphate: Given IV
Indium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Remission</title>
          <description>Median time to relapse after achieving complete remission (CR). CR is defined as complete resolution of all signs of myelodysplasia or leukemia for at least 4 weeks with all of the following:
Normal bone marrow with blasts &lt;5% with normal cellularity, normal megakaryopoiesis, &gt; 15% erythropoiesis and &gt; 25% granulocytopoiesis
Normalization of blood counts (no blasts, platelets &gt; 100000/mm3, granulocytes &gt;1500/mm3)
No extramedullary disease.
Relapse Criteria:
After CR: &gt;5% blasts in the bone marrow and/or peripheral blood
After partial remission (PR): increase of blasts cells in the marrow to &gt;50% of those during PR
Extramedullary disease confirmed cytologically or histologically.</description>
          <population>Study participants who relapsed after achieving complete remission after transplant.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213" lower_limit="69" upper_limit="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimation of Absorbed Radiation Doses to Normal Organs, Marrow and Tumor</title>
        <description>The amount of energy absorbed per unit weight of the organ or tissue is called absorbed dose and is expressed in units of gray (Gy). One gray dose is equivalent to one joule radiation energy absorbed per kilogram of organ or tissue weight.</description>
        <time_frame>Approximately day -20 to day -12 prior to transplant</time_frame>
        <population>All study participants who completed the study regimen.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)</title>
            <description>PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.
TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant
Cyclosporine: Given PO or IV
Fludarabine Phosphate: Given IV
Indium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Estimation of Absorbed Radiation Doses to Normal Organs, Marrow and Tumor</title>
          <description>The amount of energy absorbed per unit weight of the organ or tissue is called absorbed dose and is expressed in units of gray (Gy). One gray dose is equivalent to one joule radiation energy absorbed per kilogram of organ or tissue weight.</description>
          <population>All study participants who completed the study regimen.</population>
          <units>Gy</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average absorbed dose to the marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average absorbed dose to the liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average abosorbed dose total body</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average absorbed dose to the spleen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Number of participants who are still alive after transplant with or without disease.</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)</title>
            <description>PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.
TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant
Cyclosporine: Given PO or IV
Fludarabine Phosphate: Given IV
Indium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Number of participants who are still alive after transplant with or without disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Acute GvHD</title>
        <description>Number of participants who developed acute GVHD post-transplant, aGVHD stages:
Skin: a maculopapular eruption involving &lt; 25% BSA a maculopapular eruption involving 25 - 50% BSA generalized erythroderma generalized erythroderma with bullous formation and often with desquamation
Liver:
bilirubin 2.0 - 3.0 mg/100 mL bilirubin 3 - 5.9 mg/100 mL bilirubin 6 - 14.9 mg/100 mL bilirubin &gt; 15 mg/100 mL
Gut:
Diarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients with visible bloody diarrhea are at least stage 2 gut and grade 3 overall.
aGVHD Grades Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death</description>
        <time_frame>Up to 84 days post-transplant</time_frame>
        <population>Overall number of participants analyzed is 14 because one patient died prior to d+84 after transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)</title>
            <description>PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.
TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant
Cyclosporine: Given PO or IV
Fludarabine Phosphate: Given IV
Indium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Acute GvHD</title>
          <description>Number of participants who developed acute GVHD post-transplant, aGVHD stages:
Skin: a maculopapular eruption involving &lt; 25% BSA a maculopapular eruption involving 25 - 50% BSA generalized erythroderma generalized erythroderma with bullous formation and often with desquamation
Liver:
bilirubin 2.0 - 3.0 mg/100 mL bilirubin 3 - 5.9 mg/100 mL bilirubin 6 - 14.9 mg/100 mL bilirubin &gt; 15 mg/100 mL
Gut:
Diarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients with visible bloody diarrhea are at least stage 2 gut and grade 3 overall.
aGVHD Grades Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death</description>
          <population>Overall number of participants analyzed is 14 because one patient died prior to d+84 after transplant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 0 acute GVHD</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade I acute GVHD</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade II acute GVHD</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade III acute GVHD</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade IV acute GVHD</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Donor Chimerism</title>
        <description>Number of participants who has 100% donor chimerism within 100 days after transplant</description>
        <time_frame>Up to 100 days post-transplant</time_frame>
        <population>Overall number of participants analyzed is 14 because one patient died prior to d+84 after transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)</title>
            <description>PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.
TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant
Cyclosporine: Given PO or IV
Fludarabine Phosphate: Given IV
Indium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Donor Chimerism</title>
          <description>Number of participants who has 100% donor chimerism within 100 days after transplant</description>
          <population>Overall number of participants analyzed is 14 because one patient died prior to d+84 after transplant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Engraftment</title>
        <description>Average number of days to ANC &gt;= 500 after transplant</description>
        <time_frame>Up to 84 days post-transplant</time_frame>
        <population>Study participants with an ANC &lt;= to 500 after transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)</title>
            <description>PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.
TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant
Cyclosporine: Given PO or IV
Fludarabine Phosphate: Given IV
Indium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Engraftment</title>
          <description>Average number of days to ANC &gt;= 500 after transplant</description>
          <population>Study participants with an ANC &lt;= to 500 after transplant</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Non-relapse Mortality</title>
        <description>Transplant-related deaths within 100 days after transplant</description>
        <time_frame>Within the first 100 days following transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)</title>
            <description>PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.
TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant
Cyclosporine: Given PO or IV
Fludarabine Phosphate: Given IV
Indium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Non-relapse Mortality</title>
          <description>Transplant-related deaths within 100 days after transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe refractory GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bacterial infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) will be monitored and recorded in study-specific case report forms (CRFs) from the time of first exposure to an investigational agent (i.e., the start of the Indium-111-DOTA-BC8 infusion) through day +100 after transplant or through discharge prior to that date from the SCCA system to the care of the patientâ€™s primary physician.</time_frame>
      <desc>Non-hematologic adverse events of â‰¥ grade 3, possibly related events of grade 2 that have not previously been observed with components of the study regimen, and all serious adverse events will be captured in protocol-specific case report forms. Beyond day +100, disease progression, development of secondary malignancies, and survival only will be collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)</title>
          <description>PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0. TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE) Version 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin infection</sub_title>
                <description>Cellulitis</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE) Version 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Mucositis, oral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Edema trunk</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Coag negative staph infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>CMV reactivation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection - Rhinovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection - Rhinorrea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection - Metapneumovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscle weakness, lower limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscle weakness, trunk</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The highest dose achieved was 28 Gy but none of the patients experienced a DLT. Thus, the MTD was not reached.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Brenda Sandmaier, MD</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>(206) 667-4961</phone>
      <email>bsandmai@fredhtuch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

